Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multimodality therapy for head and neck cancer.

Mary K Klein1

  • 1Southwest Veterinary Oncology, 141 East Fort Lowell Road, Tucson, AZ 85705, USA. mkkl@mindspring.com

The Veterinary Clinics of North America. Small Animal Practice
|July 11, 2003
PubMed
Summary

Advancements in radiation therapy can reduce side effects for pets with nasal tumors. Combining radiation with chemotherapy or immunotherapy may offer new hope for treating challenging canine and feline cancers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase II study of the oral selective inhibitor of nuclear export (SINE) KPT-335 (verdinexor) in dogs with lymphoma.

BMC veterinary research·2018
Same author

Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.

BMC veterinary research·2015
Same author

Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study.

PloS one·2015
Same author

Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses.

Science translational medicine·2014
Same author

Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor.

American journal of veterinary research·2011
Same author

Response rate after administration of a single dose of doxorubicin in dogs with B-cell or T-cell lymphoma: 41 cases (2006-2008).

Journal of the American Veterinary Medical Association·2010

Area of Science:

  • Veterinary Oncology
  • Radiation Oncology
  • Medical Oncology

Background:

  • Current treatments for canine and feline nasal carcinoma have limitations.
  • Incompletely excised large oral tumors require additional therapeutic strategies.
  • Metastatic potential in tumors like melanoma necessitates multimodal approaches.

Purpose of the Study:

  • To explore the potential benefits of refined radiation therapy techniques in veterinary oncology.
  • To investigate the addition of adjuvant therapies, including chemotherapy and chemoradiation, for canine and feline cancers.
  • To highlight the unexplored potential of chemoradiation in veterinary medicine, particularly for feline squamous cell carcinoma.

Main Methods:

  • Review of current therapeutic strategies for nasal and oral tumors in dogs and cats.

Related Experiment Videos

  • Discussion of the role of chemotherapy (e.g., carboplatin for melanoma) as an adjuvant therapy.
  • Exploration of the concept of chemoradiation and its potential application in veterinary oncology.

    • Main Results:

    • Refined radiation therapy techniques are expected to decrease morbidity in canine and feline nasal carcinoma patients.
    • Radiation therapy is recommended for incompletely excised large oral tumors.
    • Carboplatin shows activity in melanomas, with ongoing trials.
    • Chemoradiation, a standard in human head and neck cancers, is largely unexplored in veterinary medicine.

    Conclusions:

    • Improved radiation therapy can reduce side effects and allow for adjuvant treatments in pets with nasal tumors.
    • Chemotherapy, particularly carboplatin, is a consideration for tumors with metastatic potential like melanoma.
    • Chemoradiation holds promise for treating feline squamous cell carcinoma, where current regimens are often ineffective.
    • Immunotherapy and targeted biologics represent future directions in veterinary cancer treatment.